Influenza Antiviral Drugs Market, Global Outlook and Forecast 2022-2028

January 2022 | 104 pages | ID: I844BFCBFA8EEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Influenza Antiviral Drugs in Global, including the following market information:

Global Influenza Antiviral Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Influenza Antiviral Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oseltamivir Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Influenza Antiviral Drugs include GSK, Boehringer Ingelheim, Merck, Novartis, Beximco Pharmaceuticals, Pfizer, Roche, Johnson & Johnson and Sanofi, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Influenza Antiviral Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Influenza Antiviral Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Influenza Antiviral Drugs Market Segment Percentages, by Type, 2021 (%)

• Oseltamivir
• Zanamivir
• Peramivir
• Adamantanes
• Others

Global Influenza Antiviral Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Influenza Antiviral Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Pharmacies
• Others

Global Influenza Antiviral Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Influenza Antiviral Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Influenza Antiviral Drugs revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Influenza Antiviral Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• GSK
• Boehringer Ingelheim
• Merck
• Novartis
• Beximco Pharmaceuticals
• Pfizer
• Roche
• Johnson & Johnson
• Sanofi
• Cipla Limited
• Natco Pharma
• Seqirus
• Adamas Pharmaceuticals, Inc.
• Teva Pharmaceuticals
• Daiichi Sankyo Company

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Influenza Antiviral Drugs Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Influenza Antiviral Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL INFLUENZA ANTIVIRAL DRUGS OVERALL MARKET SIZE

2.1 Global Influenza Antiviral Drugs Market Size: 2021 VS 2028
2.2 Global Influenza Antiviral Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Influenza Antiviral Drugs Players in Global Market
3.2 Top Global Influenza Antiviral Drugs Companies Ranked by Revenue
3.3 Global Influenza Antiviral Drugs Revenue by Companies
3.4 Top 3 and Top 5 Influenza Antiviral Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Influenza Antiviral Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Influenza Antiviral Drugs Players in Global Market
  3.6.1 List of Global Tier 1 Influenza Antiviral Drugs Companies
  3.6.2 List of Global Tier 2 and Tier 3 Influenza Antiviral Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Influenza Antiviral Drugs Market Size Markets, 2021 & 2028
  4.1.2 Oseltamivir
  4.1.3 Zanamivir
  4.1.4 Peramivir
  4.1.5 Adamantanes
  4.1.6 Others
4.2 By Type - Global Influenza Antiviral Drugs Revenue & Forecasts
  4.2.1 By Type - Global Influenza Antiviral Drugs Revenue, 2017-2022
  4.2.2 By Type - Global Influenza Antiviral Drugs Revenue, 2023-2028
  4.2.3 By Type - Global Influenza Antiviral Drugs Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Influenza Antiviral Drugs Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Ambulatory Surgical Centers
  5.1.5 Pharmacies
  5.1.6 Others
5.2 By Application - Global Influenza Antiviral Drugs Revenue & Forecasts
  5.2.1 By Application - Global Influenza Antiviral Drugs Revenue, 2017-2022
  5.2.2 By Application - Global Influenza Antiviral Drugs Revenue, 2023-2028
  5.2.3 By Application - Global Influenza Antiviral Drugs Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Influenza Antiviral Drugs Market Size, 2021 & 2028
6.2 By Region - Global Influenza Antiviral Drugs Revenue & Forecasts
  6.2.1 By Region - Global Influenza Antiviral Drugs Revenue, 2017-2022
  6.2.2 By Region - Global Influenza Antiviral Drugs Revenue, 2023-2028
  6.2.3 By Region - Global Influenza Antiviral Drugs Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Influenza Antiviral Drugs Revenue, 2017-2028
  6.3.2 US Influenza Antiviral Drugs Market Size, 2017-2028
  6.3.3 Canada Influenza Antiviral Drugs Market Size, 2017-2028
  6.3.4 Mexico Influenza Antiviral Drugs Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Influenza Antiviral Drugs Revenue, 2017-2028
  6.4.2 Germany Influenza Antiviral Drugs Market Size, 2017-2028
  6.4.3 France Influenza Antiviral Drugs Market Size, 2017-2028
  6.4.4 U.K. Influenza Antiviral Drugs Market Size, 2017-2028
  6.4.5 Italy Influenza Antiviral Drugs Market Size, 2017-2028
  6.4.6 Russia Influenza Antiviral Drugs Market Size, 2017-2028
  6.4.7 Nordic Countries Influenza Antiviral Drugs Market Size, 2017-2028
  6.4.8 Benelux Influenza Antiviral Drugs Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Influenza Antiviral Drugs Revenue, 2017-2028
  6.5.2 China Influenza Antiviral Drugs Market Size, 2017-2028
  6.5.3 Japan Influenza Antiviral Drugs Market Size, 2017-2028
  6.5.4 South Korea Influenza Antiviral Drugs Market Size, 2017-2028
  6.5.5 Southeast Asia Influenza Antiviral Drugs Market Size, 2017-2028
  6.5.6 India Influenza Antiviral Drugs Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Influenza Antiviral Drugs Revenue, 2017-2028
  6.6.2 Brazil Influenza Antiviral Drugs Market Size, 2017-2028
  6.6.3 Argentina Influenza Antiviral Drugs Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Influenza Antiviral Drugs Revenue, 2017-2028
  6.7.2 Turkey Influenza Antiviral Drugs Market Size, 2017-2028
  6.7.3 Israel Influenza Antiviral Drugs Market Size, 2017-2028
  6.7.4 Saudi Arabia Influenza Antiviral Drugs Market Size, 2017-2028
  6.7.5 UAE Influenza Antiviral Drugs Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 GSK
  7.1.1 GSK Corporate Summary
  7.1.2 GSK Business Overview
  7.1.3 GSK Influenza Antiviral Drugs Major Product Offerings
  7.1.4 GSK Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.1.5 GSK Key News
7.2 Boehringer Ingelheim
  7.2.1 Boehringer Ingelheim Corporate Summary
  7.2.2 Boehringer Ingelheim Business Overview
  7.2.3 Boehringer Ingelheim Influenza Antiviral Drugs Major Product Offerings
  7.2.4 Boehringer Ingelheim Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.2.5 Boehringer Ingelheim Key News
7.3 Merck
  7.3.1 Merck Corporate Summary
  7.3.2 Merck Business Overview
  7.3.3 Merck Influenza Antiviral Drugs Major Product Offerings
  7.3.4 Merck Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.3.5 Merck Key News
7.4 Novartis
  7.4.1 Novartis Corporate Summary
  7.4.2 Novartis Business Overview
  7.4.3 Novartis Influenza Antiviral Drugs Major Product Offerings
  7.4.4 Novartis Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.4.5 Novartis Key News
7.5 Beximco Pharmaceuticals
  7.5.1 Beximco Pharmaceuticals Corporate Summary
  7.5.2 Beximco Pharmaceuticals Business Overview
  7.5.3 Beximco Pharmaceuticals Influenza Antiviral Drugs Major Product Offerings
  7.5.4 Beximco Pharmaceuticals Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.5.5 Beximco Pharmaceuticals Key News
7.6 Pfizer
  7.6.1 Pfizer Corporate Summary
  7.6.2 Pfizer Business Overview
  7.6.3 Pfizer Influenza Antiviral Drugs Major Product Offerings
  7.6.4 Pfizer Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.6.5 Pfizer Key News
7.7 Roche
  7.7.1 Roche Corporate Summary
  7.7.2 Roche Business Overview
  7.7.3 Roche Influenza Antiviral Drugs Major Product Offerings
  7.7.4 Roche Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.7.5 Roche Key News
7.8 Johnson & Johnson
  7.8.1 Johnson & Johnson Corporate Summary
  7.8.2 Johnson & Johnson Business Overview
  7.8.3 Johnson & Johnson Influenza Antiviral Drugs Major Product Offerings
  7.8.4 Johnson & Johnson Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.8.5 Johnson & Johnson Key News
7.9 Sanofi
  7.9.1 Sanofi Corporate Summary
  7.9.2 Sanofi Business Overview
  7.9.3 Sanofi Influenza Antiviral Drugs Major Product Offerings
  7.9.4 Sanofi Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.9.5 Sanofi Key News
7.10 Cipla Limited
  7.10.1 Cipla Limited Corporate Summary
  7.10.2 Cipla Limited Business Overview
  7.10.3 Cipla Limited Influenza Antiviral Drugs Major Product Offerings
  7.10.4 Cipla Limited Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.10.5 Cipla Limited Key News
7.11 Natco Pharma
  7.11.1 Natco Pharma Corporate Summary
  7.11.2 Natco Pharma Business Overview
  7.11.3 Natco Pharma Influenza Antiviral Drugs Major Product Offerings
  7.11.4 Natco Pharma Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.11.5 Natco Pharma Key News
7.12 Seqirus
  7.12.1 Seqirus Corporate Summary
  7.12.2 Seqirus Business Overview
  7.12.3 Seqirus Influenza Antiviral Drugs Major Product Offerings
  7.12.4 Seqirus Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.12.5 Seqirus Key News
7.13 Adamas Pharmaceuticals, Inc.
  7.13.1 Adamas Pharmaceuticals, Inc. Corporate Summary
  7.13.2 Adamas Pharmaceuticals, Inc. Business Overview
  7.13.3 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Major Product Offerings
  7.13.4 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.13.5 Adamas Pharmaceuticals, Inc. Key News
7.14 Teva Pharmaceuticals
  7.14.1 Teva Pharmaceuticals Corporate Summary
  7.14.2 Teva Pharmaceuticals Business Overview
  7.14.3 Teva Pharmaceuticals Influenza Antiviral Drugs Major Product Offerings
  7.14.4 Teva Pharmaceuticals Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.14.5 Teva Pharmaceuticals Key News
7.15 Daiichi Sankyo Company
  7.15.1 Daiichi Sankyo Company Corporate Summary
  7.15.2 Daiichi Sankyo Company Business Overview
  7.15.3 Daiichi Sankyo Company Influenza Antiviral Drugs Major Product Offerings
  7.15.4 Daiichi Sankyo Company Influenza Antiviral Drugs Revenue in Global Market (2017-2022)
  7.15.5 Daiichi Sankyo Company Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Influenza Antiviral Drugs Market Opportunities & Trends in Global Market
Table 2. Influenza Antiviral Drugs Market Drivers in Global Market
Table 3. Influenza Antiviral Drugs Market Restraints in Global Market
Table 4. Key Players of Influenza Antiviral Drugs in Global Market
Table 5. Top Influenza Antiviral Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Influenza Antiviral Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Influenza Antiviral Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Influenza Antiviral Drugs Product Type
Table 9. List of Global Tier 1 Influenza Antiviral Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Influenza Antiviral Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Influenza Antiviral Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Influenza Antiviral Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Influenza Antiviral Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Influenza Antiviral Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Influenza Antiviral Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Influenza Antiviral Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Influenza Antiviral Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Influenza Antiviral Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Influenza Antiviral Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Influenza Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Influenza Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Influenza Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Influenza Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Influenza Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 30. GSK Corporate Summary
Table 31. GSK Influenza Antiviral Drugs Product Offerings
Table 32. GSK Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Boehringer Ingelheim Corporate Summary
Table 34. Boehringer Ingelheim Influenza Antiviral Drugs Product Offerings
Table 35. Boehringer Ingelheim Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Merck Corporate Summary
Table 37. Merck Influenza Antiviral Drugs Product Offerings
Table 38. Merck Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Novartis Corporate Summary
Table 40. Novartis Influenza Antiviral Drugs Product Offerings
Table 41. Novartis Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Beximco Pharmaceuticals Corporate Summary
Table 43. Beximco Pharmaceuticals Influenza Antiviral Drugs Product Offerings
Table 44. Beximco Pharmaceuticals Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Pfizer Corporate Summary
Table 46. Pfizer Influenza Antiviral Drugs Product Offerings
Table 47. Pfizer Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Roche Corporate Summary
Table 49. Roche Influenza Antiviral Drugs Product Offerings
Table 50. Roche Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Johnson & Johnson Corporate Summary
Table 52. Johnson & Johnson Influenza Antiviral Drugs Product Offerings
Table 53. Johnson & Johnson Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 54. Sanofi Corporate Summary
Table 55. Sanofi Influenza Antiviral Drugs Product Offerings
Table 56. Sanofi Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Cipla Limited Corporate Summary
Table 58. Cipla Limited Influenza Antiviral Drugs Product Offerings
Table 59. Cipla Limited Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 60. Natco Pharma Corporate Summary
Table 61. Natco Pharma Influenza Antiviral Drugs Product Offerings
Table 62. Natco Pharma Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 63. Seqirus Corporate Summary
Table 64. Seqirus Influenza Antiviral Drugs Product Offerings
Table 65. Seqirus Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 66. Adamas Pharmaceuticals, Inc. Corporate Summary
Table 67. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product Offerings
Table 68. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 69. Teva Pharmaceuticals Corporate Summary
Table 70. Teva Pharmaceuticals Influenza Antiviral Drugs Product Offerings
Table 71. Teva Pharmaceuticals Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 72. Daiichi Sankyo Company Corporate Summary
Table 73. Daiichi Sankyo Company Influenza Antiviral Drugs Product Offerings
Table 74. Daiichi Sankyo Company Influenza Antiviral Drugs Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Influenza Antiviral Drugs Segment by Type in 2021
Figure 2. Influenza Antiviral Drugs Segment by Application in 2021
Figure 3. Global Influenza Antiviral Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Influenza Antiviral Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Influenza Antiviral Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Influenza Antiviral Drugs Revenue in 2021
Figure 8. By Type - Global Influenza Antiviral Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Influenza Antiviral Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Influenza Antiviral Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Influenza Antiviral Drugs Revenue Market Share, 2017-2028
Figure 12. US Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Influenza Antiviral Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Influenza Antiviral Drugs Revenue Market Share, 2017-2028
Figure 24. China Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Influenza Antiviral Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Influenza Antiviral Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Influenza Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. GSK Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Boehringer Ingelheim Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Merck Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novartis Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Beximco Pharmaceuticals Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Pfizer Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Roche Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Johnson & Johnson Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Sanofi Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Cipla Limited Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Natco Pharma Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Seqirus Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Teva Pharmaceuticals Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Daiichi Sankyo Company Influenza Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)